Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 5/20 | 0.55 |
| ▸ | CES1 | P23141 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 7/20 | 0.50 |
| ▸ | MAOB | P27338 | 7/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30541907 | 1.00 | TGM2 (0.55) | TGM2CES1ALDH1A1MAOAMAOB | |
| SCHEMBL2788213 | 0.86 | MAOA (0.66) | TGM2CES1ALDH1A1MAOAMAOB | |
| SCHEMBL2372316 | 0.81 | CES1 (0.58) | TGM2CES1ALDH1A1MAOAMAOB | |
| SCHEMBL30120589 | 0.81 | CES1 (0.58) | TGM2CES1ALDH1A1MAOAMAOB | |
| SCHEMBL13401353 | 0.81 | TGM2 (0.55) | TGM2CES1ALDH1A1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL11435666 | 0.80 | CES1 (0.57) | TGM2CES1ALDH1A1MAOAMAOB | |
| SCHEMBL4202180 | 0.79 | CES1 (0.56) | TGM2CES1ALDH1A1MAOAMAOB | |
| SCHEMBL29657257 | 0.76 | ROS1 (0.67) | TGM2CES1ALDH1A1MAOAMAOB | |
| SCHEMBL281743 | 0.76 | ROS1 (0.67) | TGM2CES1ALDH1A1MAOAMAOB | |
| SCHEMBL4445322 | 0.76 | CES1 (0.53) | TGM2CES1ALDH1A1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112180007-A | Metabolics-based diagnostic marker for generalized pustular psoriasis and application thereof | 上海市皮肤病医院 | 2021-01-05 | — | — | CN | claimed |
| US-20230327205-A1 | ISATIN DERIVATIVE REDOXAMER FOR ELECTROCHEMICAL DEVICE | UCHICAGO ARGONNE, LLC. (US) | 2023-10-12 | — | — | US | disclosed |
| CN-112180007-B | Metabonomics-based diagnosis marker for generalized pustular psoriasis and application thereof | 上海市皮肤病医院 | 2023-08-18 | — | — | CN | disclosed |
| CN-112180007-B | Metabonomics-based diagnosis marker for generalized pustular psoriasis and application thereof | 上海市皮肤病医院 | 2023-08-18 | — | — | CN | disclosed |
| US-11715844-B2 | Isatin derivative redoxmer for electrochemical device | UCHICAGO ARGONNE, LLC (US) | 2023-08-01 | — | — | US | disclosed |
| US-11312712-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-04-26 | — | — | US | disclosed |
| US-20210284641-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-16 | — | — | US | disclosed |
| CN-112180007-A | Metabolics-based diagnostic marker for generalized pustular psoriasis and application thereof | 上海市皮肤病医院 | 2021-01-05 | — | — | CN | disclosed |
| CN-112180007-A | Metabolics-based diagnostic marker for generalized pustular psoriasis and application thereof | 上海市皮肤病医院 | 2021-01-05 | — | — | CN | disclosed |
| US-10479765-B2 | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-11-19 | — | — | US | disclosed |
| US-8053442-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-8053442-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| CN-102015711-A | Spiro-indole derivatives for the treatment of parasitic diseases | NOVARTIS AG | 2011-04-13 | — | — | CN | disclosed |
| EP-2285808-A1 | SPIRO-INDOLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | Novartis AG (CH) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009132921-A1 | SPIRO-INDOLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009132921-A1 | SPIRO-INDOLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090275560-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-05 | — | — | US | disclosed |
| US-20090275560-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-05 | — | — | US | disclosed |
| US-20090275560-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-05 | — | — | US | disclosed |
| US-7429604-B2 | Six-membered heterocycles useful as serine protease inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284641-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | TGM2 2460/4885CES1 2261/4885ALDH1A1 721/4885 |
| US-10479765-B2 | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents | AADAC, NFKBIA, NOD2 | TGM2 566/4885CES1 289/4885ALDH1A1 1598/4885 |
| US-20230327205-A1 | ISATIN DERIVATIVE REDOXAMER FOR ELECTROCHEMICAL DEVICE | NDUFS5, SQOR, NDUFS7 | TGM2 3290/4885CES1 4583/4885ALDH1A1 1221/4885 |
| US-20090275560-A1 | ORGANIC COMPOUNDS | OTC, PC, OAT | TGM2 1962/4885CES1 863/4885ALDH1A1 449/4885 |
| US-11312712-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | TGM2 2460/4885CES1 2261/4885ALDH1A1 721/4885 |
| US-11715844-B2 | Isatin derivative redoxmer for electrochemical device | SQOR, SLC39A14, NDUFS5 | TGM2 2662/4885CES1 4335/4885ALDH1A1 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.